melatonin (Circadin)

DRUG3 trials

Sponsors

Neurim Pharmaceuticals Ltd., University of Oslo, Thammasat University

Conditions

BlindnessMelasmaNon-24 Hour Sleep-Wake DisorderRecurrenceSpinal Cord Injured, TetraplegiaTreatment Outcome

Phase 1

The Role of Melatonin in the Regulation of Blood Coagulation

CompletedNCT01741389

University of OsloSpinal Cord Injured, Tetraplegia

Start: 2012-12-31End: 2014-03-31Updated: 2017-10-16

Phase 2

Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects

CompletedNCT00972075

Neurim Pharmaceuticals Ltd.Blindness, Non-24 Hour Sleep-Wake Disorder

Start: 2006-02-28End: 2007-10-31Updated: 2009-09-09

Phase 4

Effectiveness of Oral Melatonin vs Oral Tranexamic Acid in the Treatment and Recurrence of Melasma

Active, not recruitingNCT07034560

Thammasat UniversityMelasma, Recurrence, Treatment Outcome

Start: 2024-11-12End: 2025-11-06Updated: 2025-06-24

Related Papers

Prolonged release melatonin for improving sleep in totally blind subjects: a pilot placebo-controlled multicenter trial.

2015-01-2924 citations